14 Jul 2022
SERB Pharmaceuticals licenses Soligenix antigen to develop ricin antidote
SERB will leverage its unique broad spectrum polyclonal antibody platform, gained in its acquisition of BTG Specialty Pharmaceuticals
14 Jul 2022
SERB will leverage its unique broad spectrum polyclonal antibody platform, gained in its acquisition of BTG Specialty Pharmaceuticals
09 Jun 2022
11 Apr 2022
04 Apr 2022
14 Jan 2022
Voraxaze® is now authorized for marketing in all members states of the European Union.